Overview
Revatis S.A. is a spin-off from the University of Liège dedicated to regenerative medicine and cell therapy. The company has developed patented technology for obtaining multipotent stem cells from muscle micro-biopsies, with applications in veterinary clinical medicine and human medical research.
Key people
In the news
- Revatis strategy in some words! Thanks to BioWin.
- Revatis is pleased to announce that the Belgian medicines agency, FAMHP, has authorised a clinical study evaluating Exovet RLC100 for the treatment of keratitis in horses. Following two completed clinical studies with an autologous cell product, this is Revatis’ first authorised study with a non-immunological biological product. Exovet RLC100 is an extracellular vesicle-enriched secretome generated through a patented technology from Revatis’ proprietary muscle-derived stem cell line. Beyond its veterinary objective, the study will
- The EV-rich secretome, generated using our patented technology from our stem cell lines, exhibits remarkable properties.
- I am pleased to share that our abstract has been selected for an oral presentation at the 3rd World Congress on Targeting Extracellular Vesicles, to be held on 12–13 November 2026 in Porto, Portugal. "Cytokine priming enhances anti-neutrophil activity of an equine extracellular vesicle-enriched muscle-derived mesenchymal stem cell secretome” This work examines how cytokine priming influences the functional anti-inflammatory activity of an EV-enriched secretome produced from equine muscle-derived mesenchymal stem cells. We look
- From concept to scientific evidence Following the introduction of Axovet® MAPS (Mechanically Activated Platelet Secretome), we are pleased to share the first Scientific Brief describing the biological rationale behind this new autologous orthobiologic approach. The document reviews: • the rationale for controlled mechanical platelet activation; • the concept of collecting an autologous platelet secretome rather than administering intact platelets; • the complementary positioning of Axovet® MAPS alongside Axovet® PRP; • our
- For our veterinary branch "Revatis Vet", we are proud to introduce Axovet® MAPS "Mechanically Activated Platelet Secretome". An original concept for preparing an acellular platelet secretome through controlled mechanical activation. Developed as a complementary approach to Axovet® PRP, MAPS uses the same initial blood separation principle but follows a different biological strategy. 🔹 Axovet® PRP: cellular preparation with platelets and mononuclear cells 🔹 Axovet® MAPS: acellular platelet secretome obtained by controlled
Something wrong or missing? Send an update. Fixed within 24 hours.